Nuvectis reports Q3 2026 financial results and details the in-licensing of two drugs, ciprocopan and NXP200, while awaiting FDA updates before year-end.
Nuvectis reports Q3 2026 financial results and details the in-licensing of two drugs, ciprocopan and NXP200, while awaiting FDA updates before year-end.